Asarina Pharma recruits patients for Phase IIB trial of Sepranolone, world’s first treatment targeting PMDD, premenstrual dysphoric disorder
Patient enrolment is expected to be high for the Phase IIB clinical trial of Sepranolone, driven by strong medical need for a therapy that specifically targets PMDD, the severest form of PMS, in a market with few alternatives. Patients will be recruited in UK, Poland, Germany and Sweden.Worldwide, 4-5% of all women of a fertile age currently suffer from PMDD. Symptoms can be devastating and disabling, disrupting relationships, family and working life. Yet no therapy specifically targeting the disease is available today, and the most commonly used treatment, SSRI anti-depressants, produce